Titan’s Spheramine Fails In Parkinson’s
This article was originally published in The Pink Sheet Daily
Executive Summary
Partner Bayer Schering drops compound after Phase IIb fizzle.
You may also be interested in...
Encouraging Phase III Data Reported For Vanda’s Schizophrenia Candidate
Iloperidone could have a potential tolerability advantage over Pfizer’s Geodon.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.